BOSTON — Sempresto, Inc., a medical device company developing smartphone-integrated rescue drug delivery systems, announced the acquisition of Alerje’s mobile device–integrated autoinjector platform, including its intellectual property portfolio and associated physical assets. The platform reflects nearly a decade of product development and award-winning innovation at Alerje.
“This platform is technically sound, IP secured, and commercially relevant,” said Elizabeth Reczek, Ph.D., CEO of Sempresto. “With Sempresto’s expertise, capital, and clarity of purpose, we are well positioned to accelerate final development and deliver this life saving innovation to patients who need it most.”
Javier Evelyn, Founder and CEO of Alerje, said, “This deal represents both a capstone and a beginning. Sempresto is the right team to bring this device across the finish line, with a now dominant global IP position and deep commercialization expertise. Meanwhile, Alerje is entering an exciting new phase, doubling down on the software, diagnostics, and AI that will power food allergy care at scale.”
Sempresto said the acquisition strengthens its position in smartphone-mounted drug delivery systems and supports its efforts to bring new rescue medications to market. The agreement also allows Alerje to expand its focus on AI-enabled software solutions for food allergy management. Both companies said the transaction underscores their shared commitment to improving care for patients at risk of anaphylaxis while advancing innovations aligned with their respective core strengths.
